How many injections of evantumumab are needed in a year? How is the period and frequency of treatment determined?

Amivantamab (Amivantamab) is an EGFR-MET bispecific antibody, mainly used to treat EGFR exon 20 non-small cell lung cancer (NSCLC). During the first month of treatment, the recommended dose is weight-based intravenous infusion over two days, once a week for four weeks. This high-frequency dosing in the initial phase helps to quickly establish drug concentrations and improve efficacy, while monitoring patient tolerance to the drug.

After initial treatment, the dosing frequency of evantumumab was adjusted to once every two weeks starting at Week 5. Dosing during this phase is still based on patient weight and is usually done in one infusion. This adjustment helps reduce the frequency of patient visits while ensuring that drug concentrations remain within the effective range. Under this dosing schedule, patients would receive approximately 24 injections per year during the maintenance phase.

Treatment with evantumumab is usually continued until disease progression or intolerable side effects occur, and there is no fixed limit on the total duration of treatment. If a patient experiences significant disease progression during treatment, a change in treatment regimen may be necessary. In addition, doctors may adjust the dose or suspend treatment if a patient experiences a serious adverse reaction to the drug, such as an infusion-related reaction, severe skin toxicity, or pneumonia.

Although standard treatment regimens recommend approximately 30 injections per year (first4weeks8 pan> times+follow-up24 times), but in clinical practice, the specific treatment frequency may be adjusted according to the patient's condition. For example, some patients may be highly sensitive to the drug, and doctors may lower the dose or extend the interval between doses. Dose adjustments are also common in older patients or those with other medical conditions. Therefore, the specific dosage regimen of evantumumab needs to be individually adjusted by doctors based on the patient's condition, tolerance and treatment response to obtain the best efficacy.

Reference materials:https://www.rybrevant.com/